drugset
drugset / Trial / NCT06585462

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

NCT06585462 ↗

Phase 1 Recruiting 80 enrolled Amgen
RandomizedSequentialDouble-blindTreatment

Summary

The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.

Timeline

Start
2024-09-09
Primary completion
2026-10-01
Completion
2026-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AMG 513 Unknown — Subcutaneous

Indications

metabolic disease